Skip to main content

Table 2 Individual Patient Baseline Characteristics and Response to Treatment with Pembrolizumab

From: Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Case no. No. of prior systemic therapies Prior systemic therapies ECOG performance status Hormonal status Metastatic sites at time of studya PD-L1H-scoreb TILscorec MSI status Maximum % change from baseline
1 4 Mitotane; ACAT-inhibitor; ipilimumab; cisplatin-gemcitabine 1 Cortisol and androgen-producing 2 0 2 NA 289% increase
2 1 Mitotane 1 Non-functioning 2, 4 0 2 Stable 88% increase
3 2 Mitotane; etoposide-doxorubicin-cisplatin-mitotane 1 Androgen-producing 1, 2, 4, 5 0 1 Stable 56% increase
4 1 Etoposide-doxorubicin-cisplatin-mitotane 0 Cortisol and androgen-producing 2, 4, 5 0 2 Stable 49% increase
5 2 Mitotane; Etoposide-doxorubicin-cisplatin 1 Cortisol and androgen-producing 1, 4, 5 0 2 Stable 43% increase
6 1 Etoposide-carboplatin-mitotane 1 Non-functioning 2, 4 0 2 Stable 15% increase
7 5 Etoposide-doxorubicin-cisplatin-mitotane; ACAT-inhibitor; etoposide-carboplatin-mitotane; mitotane; ipilimumab 1 Cortisol and androgen-producing 1, 2, 4 0 2 Stable 14% increase
8 5 Mitotane; ACAT-inhibitor; etoposide-doxorubicin-cisplatin; ipilimumab; cabozantinib 1 Cortisol-producing 1, 1, 4 0 1 Stable 11% increase
9 1 Mitotane 0 Non-functioning 4 0 1 Stable 6% increase
10 1 Mitotane 1 Cortisol and androgen-producing 1, 2, 3, 5 0 1 Stable 5% increase
11 2 Mitotane; etoposide-doxorubicin-cisplatin 1 Non-functioning 1, 2, 3, 4 0 3 Stable 8% decrease
12 2 Etoposide-doxorubicin-cisplatin-mitotane; mitotane 1 Non-functioning 2 NA NA Stable 24% decrease
13 3 Mitotane; etoposide-doxorubicin-cisplatin; gemcitabine-docetaxel 1 Cortisol and androgen-producing 1, 6 NA NA Stable 41% decrease
14 4 Mitotane; etoposide-doxorubicin-cisplatin-mitotane; etoposide-carboplatin; ipilimumab 0 Non-functioning 1, 2 0 0 NA 53% decrease
15 1 Etoposide-doxorubicin-cisplatin-mitotane 1 Androgen-producing 1, 2, 4, 5 0 1 Stable Not restaged
16 3 Etoposide, doxorubicin, carboplatin-mitotane; apatinib; streptozocin 1 Androgen-producing 1, 2, 4 0 2 Isolated loss of PMS2 (internal positive control) Not restaged
  1. Abbreviations: ACAT-inhibitor Acyl-coenzyme A:cholesterol O-acyltransferase inhibitor, ECOG Eastern Cooperative Oncology Group, MSI Microsatellite instability, NA Not available, PD-L1 Programmed cell death ligand-1, TIL Tumor-infiltrating lymphocyte
  2. aMetastatic sites: 1, liver; 2, lung; 3, bone; 4, adrenal bed; 5, lymph nodes; 6, other
  3. bPD-L1 characterization based on the percentage and intensity of membrane staining
  4. cTILs within tumor nests were scored on a scale from 0 to 3: 0 for absence of TILs, 1 for a few TILs, 2 for a moderate amount of TILs, and 3 for intense intratumoral lymphocytic infiltration